



Docket: 21 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang et al.

Serial No: 09/528,225

Examiner: Saoud, Christine J.

Filed: March 21, 2000

Group Art Unit: 1647

For: Chimeric Proteins For Diagnosis and Treatment of Diabetes

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

( ) This information disclosure statement is being filed within three (3) months of the filing date of this application.

( ) This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

( ) To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.

( ) Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).

( ) Enclosed is a petition under 37 C.F.R. §1.97 (d)

(.) Please charge the petition fee of \$130.00 required under 37 C.F.R. §1.17 (i)(1) to Deposit Account No. 01-0483.

( ) As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R. §1.113 or the mailing of a notice of allowance under 37 C.F.R. §1.113, and is accompanied by the \$220.00 fee as provided for in 37 C.F.R. §1.17(p).

( ) Please charge the \$240.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. 01-0483.

(x) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. **TWO COPIES OF THIS SHEET ARE ENCLOSED.**

Early and favorable consideration of the case is respectfully requested.

Dated: Nov. 12, 2004



Mark Farber  
Registration No. 34,159  
Attorney for Applicants

Mark Farber  
C/O  
Alexion Pharmaceuticals, Inc.  
352 Knotter Drive  
Cheshire, CT 06410  
(203) 271-8319

Form PTO-1449 U.S. DEPARTMENT OF  
COMMERCE PATENT AND TRADEMARK  
OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

ATTY. DOCKET NO.

21 US

SERIAL NO.

09/528,225

(Use several sheets if necessary)

APPLICANT

Wang et al

FILING DATE

March 21, 2000

GROUP Art Unit:

1647

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- |   |
|---|
| Barnett, LA et al. 1993 J Neuroimmunol 44:15-26; Enhancement of Autoimmune Disease Using Recombinant Vaccinia Virus Encoding Myelin Proteolipid Protein.  |
| Boehmo and Leardo 1993 Eur J. Immunol 23:1552-1560.   |
| Chiang, B-L et al. 1992 Int. Arch Allergy Immunol 98:181-188: Prospects of Vaccination in Autoimmune Disease  |
| Chen et al. 1994 Science 265:1237-1240.   |
| Chou 1990 Prediction of Protein Structure and the Principles of Protein conformation Plenum Press 549-586.  |
| Chou, YK et al 1992. J. Neuroimmunol 38: 105-114: Frequency of T Cells Specific for Myelin Basic Protein and Myelin Proteolipid Protein in Blood and Cerebrospinal Fluid in Multiple Sclerosis. |
| Duvall and Wyllie 1986 Immunol Today 7:115 et seq.  |
| Einstein et al. 1962: J. Neurochem: 9:252-361: The isolation from bovine spinal cord of a homogeneous protein with Encephalitogenic Activities.   |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF  
COMMERCE PATENT AND TRADEMARK  
OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

21 US

SERIAL NO.

09/528,225

APPLICANT

Wang et al

FILING DATE

March 21, 2000

GROUP Art Unit:

1647

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fritz, RB et al. 1994 J. Neuroimmunol 51:1-6: Encephalitogenicity of Myelin basic Protein Exon-2 Peptide in Mice.
	Griffin et al., 1995 Am J. Pathol 147:845-857.
	Grosjean, H. et al. 1982 Gene 18: 199-209: Preferential codon Usage in Prokaryotic Genes: The Optimal codon-Anticodon Interaction Energy and The Selective Codon Usage in Efficiently Expressed Genes.
	Hernan, RA et al. 1992 Biochemistry 31: 8619-8628: Human Hemoglobin Expression in Escherichia Coli: Importance of Optimal Codon Usage.
	Kaufman et al., 1993 Nature 1992 J Clin Invest 98:283-292
	Kim et al., 1993:Immunol Invest 22 (3):219-227.
	Lockshin and Zekeri, 1991: Apoptosis: The Molecular Basis of Cell Death, Tomei and Cope (eds), Cold Spring Harbor Laboratory Press, Plainview, New York, pp47 et seq.
	Lohman et al., 1994 Lancet 343:1607-1608.
	McRae, B. et al. 1992 J Neuroimmunol 38:229-240: Induction of Active and Adoptive Relapsing Experimental Autoimmune Encephalomyelitis (EAE) Using an Encephalitogenic Epitope of Proteolipid Protein.
	Miller, A. et al. 1992 J Neuroimmunol 39:243-350
	Mitchinson 1964 Proc R. Soc London Ser B 161: 275-280: Induction of Immunological Paralysis in two zones of dosage.
	Mullis et al., Eds., 1994 The Polymerase Chain Reaction Springer-Verlag, New York, NY.
	Oettinger, H. et al. 1993 J Neuroimmunol 44:157-162. Biological Activity of Recombinant Human Myelin Basic Protein.
	Pelfry, et al., 1993 J Neuroimmunol 46:33-42: Identification of Novel T Cell Epitope of Human Proteolipid (residues 40-60) Recognized by Proliferative and Cytolytic CD4+ T cells From Multiple Sclerosis Patients.
	Pelfry, et al. 1994 J Neuroimmunol 53:153-161: Identification of A Second T Cell Epitope of Human Proteolipid Protein (residues 89-106) recognized by proliferative and Cytolytic CD4+ T Cells from Multiple Sclerosis Patients.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF  
COMMERCE PATENT AND TRADEMARK  
OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

ATTY. DOCKET NO.

21 US

SERIAL NO.

09/528,225

(Use several sheets if necessary)



APPLICANT

Wang et al

FILING DATE

March 21, 2000

GROUP Art Unit:

1647

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Pereyra, P. et al. 1988 Neurochem Res 13: 583-595: Triton X-100 Extractions of Central Nervous System Myelin Indicate a Possible Role for the Minor Myelin Proteins in the Stability of Lamellae
	Roth, HJ et al. 1987 J Neurosci res 17:321-328:Evidence for the Expression of Four Myelin Basic Protein Variants in the Developing Human Spinal Cord Through cDNA Cloning.
	Segal, et al. 1994 J. Neuroimmunol 51:7-19: Experimental Allergic encephalomyelitis Induced by the Peptide Encoded by Exon 2 of the MBP Gene, A Peptide Implicated in Remyelination.
	Sercarz et al. 1959 Nature Vol. 184: 1080-1082-Specific Inhibition of Antibody Formation During Immunological Paralysis and Unresponsiveness.
	Smith et al. Nature Vol. 337 12 January 1989-Antidodies to CD3/T-cell receptor Complex Induce Death By Apoptosis in Immature T Cells in Thymic Cultures.
	Sriram et al. Cellular Immunology 75, 378-382 (1983)-Administration of Myelin Basic Protein-Coupled Spleen Cells Prevents Experimental Allergic Encephalitis.
	Streicher and Stoffel: 1989. Biol. Chem Hoppe-Seyler 370:503-510: The Organization of The Human Myelin Basic Protein Gene, Comparasion with the Mouse Gene.
	Traugott, U. et al. 1982. J Neurol Sci 56:65-73: Chronic Relapsing Experimental Autoimmune Encephalomyelitis, treatment with Combinations of Myelin Components Promotes Clinical and Structural Recovery.
	Tuohy, V. et al. 1992 J. Neuroimmunol: 39: 67-74: Myelin Proteolipid Protein : Minimum Sequence Requirements for Active Induction of Autoimmune Encephalomyelitis in SWR/J and SJL/Mice.
	Van Der Veen, R. et al. 1992 J. Neuroimmunol 38: 139-146: Immune Processing of Proteolipid Protein By Subsets of Antigen-Presenting Spleen Cells.
	Van Noort, J. et al. 1994 J Chromatogr B. 653:155-161: Fractionation of Central Nervous System Myelin Proteins by Reversed-Phase High-Performance Liquid Chromatography.
	Voskuil, r. et al. 1993 J. Neuroimmunol: 42: 187-192 T-Lymphocyte Recognition of a Portion of Myelin Basic Protein Encoded by an Exon Expressed During Myelination.
	Voskuhl r. et al 1993 J. Neuroimmunol 46: 173-144: A Novel Candidate Autoantigen in a Multiplex Family with Multiple Sclerosis: Prevalence of T-Lympocytes Specific For and MBP Epitope Unique to Myelination.
	Whitham, R. et al 1991: J. Immunol 147: 101-107: Lymphocytes From SJL/J Mice Immunized with Spinal Cord Respond Selectively to a Peptide of Proteolipid Protein and Transfer Relapsing Demyelinating Experimental Autoimmune Encephalomyelitis.
	Wen et al. J. clin. Invest Vol 102, Number 5, September 1998, 947-957-Induction of Insulinitis by Glutamic Acid Decarboxylase Peptide-Specific and HLA-DQ8-restricted CD4 T Cells from Human DQ Transgenic Mice.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.